Header Logo

Connection

MURALI CHINTAGUMPALA to Combined Modality Therapy

Back to Details
This is a "connection" page, showing publications MURALI CHINTAGUMPALA has written about Combined Modality Therapy.
MURALI CHINTAGUMPALA
Connection Strength
0.978
Combined Modality Therapy
  1. Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children's Oncology Group Trial (ARET0321). J Clin Oncol. 2022 11 20; 40(33):3839-3847.
    View in: PubMed
    Score: 0.156
  2. Multimodality Treatment of Pediatric Esthesioneuroblastoma. Pediatr Blood Cancer. 2016 Mar; 63(3):465-70.
    View in: PubMed
    Score: 0.098
  3. Local control after craniospinal irradiation, intensity-modulated radiotherapy boost, and chemotherapy in childhood medulloblastoma. Cancer. 2011 Feb 01; 117(3):635-41.
    View in: PubMed
    Score: 0.069
  4. Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma. Int J Radiat Oncol Biol Phys. 2010 Dec 01; 78(5):1445-50.
    View in: PubMed
    Score: 0.066
  5. A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. Neuro Oncol. 2009 Feb; 11(1):33-40.
    View in: PubMed
    Score: 0.060
  6. Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir. J Clin Oncol. 2005 Nov 01; 23(31):7927-35.
    View in: PubMed
    Score: 0.049
  7. Outcomes of Wilms tumor therapy in Lilongwe, Malawi, 2016-2021: Successes and ongoing research priorities. Pediatr Blood Cancer. 2023 05; 70(5):e30242.
    View in: PubMed
    Score: 0.041
  8. Treatment controversies in medulloblastoma. Curr Opin Oncol. 2001 May; 13(3):154-9.
    View in: PubMed
    Score: 0.036
  9. Disease Control and Patterns of Failure After Proton Beam Therapy for Rhabdomyosarcoma. Int J Radiat Oncol Biol Phys. 2021 03 01; 109(3):718-725.
    View in: PubMed
    Score: 0.035
  10. Results of Treatment for Patients With Multicentric or Bilaterally Predisposed Unilateral Wilms Tumor (AREN0534): A report from the Children's Oncology Group. Cancer. 2020 08 01; 126(15):3516-3525.
    View in: PubMed
    Score: 0.034
  11. Effect of sensorineural hearing loss on neurocognitive and adaptive functioning in survivors of pediatric embryonal brain tumor. J Neurooncol. 2020 Jan; 146(1):147-156.
    View in: PubMed
    Score: 0.033
  12. Patterns of failure and toxicity profile following proton beam therapy for pediatric bladder and prostate rhabdomyosarcoma. Pediatr Blood Cancer. 2019 11; 66(11):e27952.
    View in: PubMed
    Score: 0.032
  13. Patterns of failure following proton beam therapy for head and neck rhabdomyosarcoma. Radiother Oncol. 2019 05; 134:143-150.
    View in: PubMed
    Score: 0.031
  14. Vitreous Seeds in Retinoblastoma: Clinicopathologic Classification and Correlation. Ophthalmology. 2017 10; 124(10):1540-1547.
    View in: PubMed
    Score: 0.027
  15. Mixed neuronal-glial tumors (gangliogliomas) in children. Pediatr Neurosurg. 1996 Jun; 24(6):306-13.
    View in: PubMed
    Score: 0.026
  16. Mucoepidermoid Carcinoma in Children: A Single Institutional Experience. Pediatr Blood Cancer. 2016 Jan; 63(1):27-31.
    View in: PubMed
    Score: 0.024
  17. Outcome of patients with pilocytic astrocytoma and leptomeningeal dissemination. Int J Radiat Oncol Biol Phys. 2012 Oct 01; 84(2):350-4.
    View in: PubMed
    Score: 0.019
  18. Plasma proteome predicts chemotherapy response in osteosarcoma patients. Oncol Rep. 2011 Feb; 25(2):303-14.
    View in: PubMed
    Score: 0.017
  19. High-dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma. Pediatr Blood Cancer. 2010 Jul 15; 55(1):149-52.
    View in: PubMed
    Score: 0.017
  20. Results of treatment of patients with superficial facial rhabdomyosarcomas on protocols of the Intergroup Rhabdomyosarcoma Study Group (IRSG), 1984-1997. Pediatr Blood Cancer. 2008 May; 50(5):958-64.
    View in: PubMed
    Score: 0.015
  21. Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma. Int J Radiat Oncol Biol Phys. 2008 Mar 01; 70(3):782-7.
    View in: PubMed
    Score: 0.014
  22. A single institution experience with pediatric nasopharyngeal carcinoma: high incidence of toxicity associated with platinum-based chemotherapy plus IMRT. J Pediatr Hematol Oncol. 2007 Jul; 29(7):500-5.
    View in: PubMed
    Score: 0.014
  23. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006 Oct; 7(10):813-20.
    View in: PubMed
    Score: 0.013
  24. Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurooncol. 2006 Feb; 76(3):313-9.
    View in: PubMed
    Score: 0.012
  25. Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res. 2005 Sep 15; 65(18):8142-50.
    View in: PubMed
    Score: 0.012
  26. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol. 2005 Aug 20; 23(24):5511-9.
    View in: PubMed
    Score: 0.012
  27. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys. 2002 Mar 01; 52(3):599-605.
    View in: PubMed
    Score: 0.010
  28. Clear cell sarcoma of the kidney: an unusual presentation and review of the literature. J Pediatr Hematol Oncol. 1998 Mar-Apr; 20(2):165-8.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.